TapImmune, Inc. (OTCBB: TPIV) Trading +22%

Tallahassee, FL 10/27/11 (PennyPayDay) --Shares of micro-cap biotech TapImmune, Inc. (OTC.BB: TPIV) have seen a steady increase in volume and trading activity in recent weeks. At a volume of 1.3M (much greater than the 109,375 average volume during the regular season), shares are currently trading at $0.26, up 22%,

With the World Health Organization's recent vocal announcements of growing threats that multidrug-resistant and extensively drug-resistant forms of tuberculosis are spreading at an alarming rates in Europe, investors have once again begun to pay more attention to TPIV, which holds promise as both an anti-cancer and bio-defense play. TapImmune continues working with the likes of the Mayo Clinic and Aeras Foundation on vaccine candidates in both Cancer and Infectious Diseases.

The company has been quietly building solid relationships within industry because of the relevance of the TAP technology and BioMedReports continues to expect positive developments from the firm, particularly with CEO Dr. Glynn Wilson on the verge of presenting data from the clinic on TAP levels and its affect on disease progression. There is growing evidence now from around the world showing that TAP is indeed a key component in the antigen presentation process and where it is lacking or down regulated, disease progresses and prognosis is worse.

The Seattle based company's TAP-based prophylactic vaccine -- which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times -- may significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases.

A next generation smallpox vaccine is currently in preclinical development and the company has been busy working with Gregory Poland, the head of the Mayo Clinic's Vaccine Research Group, who is working to unite the fields of genomics and vaccinology. That work has come about, in part, because Poland and others have never been fully pleased with the existing vaccine paradigm.

PennyPayDay Disclaimer

Distributed by Viestly

Sunshine Biopharma's (OTCBB: SBFM.ob) Anti-Cancer Compound Found to be a Strong Top2 Inhibitor

Tallahassee, FL 10/25/11 (PennyPayDay) --According to the American Cancer Society, there are over 11 million Americans living with cancer, and with approximately 1.5 million new cases being diagnosed each year in the U.S. Virtually all cancers are either aggressive at the onset or become aggressive overtime. The two genes associated with aggressive forms of cancer are Her2 and Top2. Currently, Herceptin (R)*, with sales of $1,8 Billion per year, is an effective treatment for Her2 positive patients. However, there are no effective therapies on the market that target Top 2. Inhibition of Top2 activity is essential in the fight against aggressive types of cancer, including multi-resistant breast cancer.

Sunshine Biopharma Inc. (OTCBB: SBFM.ob) is a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Recently, it announced the completion of a study in which the ability of Adva-27a, its lead compound, to inhibit the activity of Top2 was measured directly. In multi-drug resistant breast cancer, the gene that encodes Top2 has been found to be amplified as much as 10-fold thereby allowing the cancer cells to make tens of thousands of Top2 molecules. Effective inhibition of Top2 activity would arrest the ability of cancer cells to multiply rapidly and spread.

In the present study the ability of Adva-27a to inhibit Topoisomerase II was measured in a concentration dependent fashion using highly purified, human Topoisomerase II alpha and concatenated plasmid DNA as a substrate. The results showed that Adva-27a is an excellent inhibitor of Topoisomerase II. Inhibition of 50% of Topoisomerase II activity (IC50) took place at a concentration of only 13.7 micromolar Adva-27a.

"An IC50 of 13.7 micromolar indicates that Adva-27a is an excellent inhibitor of Topoisomerase II", said Dr. Steve N. Slilaty, Sunshine's President and CEO. "Compounds displaying IC50's in the 75 to 100 micromolar range cannot be developed into effective drugs as the amounts which would have to be administered to patients would be too toxic. We are delighted to find that our compound has such low IC50. This is a significant milestone in our continued development of Adva-27a", he added.

PennyPayDay Disclaimer

Distributed by Viestly